High-dose, short-term, anti-inflammatory treatment with dexamethasone reduces growth and augments the effects of 5-fluorouracil on dimethyl-α-benzanthracene-induced mammary tumors in rats

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 6, 2006, Pages 477-486

  Stuhr, L E B ^a   Salnikov, A V ^b   Iversen, V V ^a   Salvesen, G ^a   Rubin, K ^b   Reed, R K ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

5 FU; Dexamethasone; Inflammatory cell infiltration; Interstitial fluid pressure; Tumor growth; Vessel density

Indexed keywords

ANTIINFLAMMATORY AGENT; CD31 ANTIGEN; DEXAMETHASONE; DIMETHYLBENZ[A]ANTHRACENE; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER MODEL; CELL INFILTRATION; CONTROLLED STUDY; DENSITY; DRUG EFFECT; DRUG EFFICACY; DRUG UPTAKE; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; TISSUE PRESSURE; TUMOR GROWTH; TUMOR VOLUME;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARCINOGENS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; EXTRACELLULAR FLUID; FEMALE; FLUOROURACIL; INJECTIONS, INTRAPERITONEAL; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33749033881     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510600788332     Document Type: Article

References (35)

1. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
2. Wiig H, Tveit E, Hultborn R, Reed R, Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 1982;42:159-64.
3. Heldin C-H, Rubin K, Pietras K, Østman A. High interstitial fluid pressure: an obstacle in cancer therapy. Nature Rev 2004;4:808-13.
4. Rubin K, Sjoquist M, Gustafsson AM, Isaksson B, Salvessen G, Reed RK. Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA. Int J Cancer 2000;1:636-43.
5. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, et al. Lowering of tumor interstitial fluid pressure specifically augments efficiency of chemotherapy. Faseb Journal 2003;17:1756-8.
6. Pietras K, Østman A, Sjøquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptor reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34.
7. Pietras K, Rubin K, Sjøblom T, Buchdunger E, Sjøquist M, Heldin CH, et al. Inhibition of PDGF receptor signalling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
8. Shapiro WR, Posner JB. Corticosteroid hormones. Effects in an experimental brain tumor. Arch Neurol 1974;30:217-21.
9. Kristjansen PEG, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 1993;53:4764-6.
10. Hofmann J, Kaiser U, Maasberg M, Havemann K. Glucocorticoid receptors and growth inhibitory effects of dexamethasone in human lung cancer cell lines. Eur J Cancer 1995;31:2053-8.
11. Denis MG, Chadeneau C, Blanchardie P, Lustenberger P. Biological effects of glucocorticoid hormones on two rat colon adenocarcinoma cell lines. J Steroid Biochem Mol Biol 1992;41:739-45.
12. Distelhorst GW. Glucocorticosteroids induce DNA fragmentation in human lymphoid leukemia cells. Blood 1988;72:1305-9.
13. Fadnes HO, Reed RK, Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 1977;14:27-36.
14. Sundberg C, Ivarsson M, Gerdin B, Rubin K. Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest 1996;74:52-466.
15. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume [review]. Physiol Rev 1993;73:1-78.
16. 2α analogs on collagen gel compaction in vitro and interstitial pressure in vivo. Am J Physiol 1998;274:663-71.
17. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-α treatment of three human melanoma xenografts. Br J Cancer 1996;74:533-6.
18. Lee I, Boucher Y, Jain RK. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res 1992;52:3237-40.
19. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
20. Lammerts E, Roswall P, Sundberg C, Gotwals PJ, Koteliansky VE, Reed RK, et al. Interference with TGF-beta 1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int J Cancer 2002;102:453-462.
21. Salnikov AV, Roswall P, Sunberg C, Gardner H, Heldin N-E, Rubin K. Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 2005;85:512-21.
22. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiology Rev 1994;74:163-219.
23. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
24. Kawashima H, Ogose A, Hayami T, Yamagiwa H, Hatano H, Hotta T, et al. Effect of dexamethasone on growth inhibition and chondrogenic maturation of human chondrosarcoma. J Orthop Sci 2003;8:341-5.
25. Kudawara I, Ueda T, Yoshikawa H, Miyama T, Yamamoto T, Nishizawa Y. In vivo inhibition of tumour growth by dexamethasone in murine osteosarcomas. Eur J Cancer 2001;37:1703-8.
26. Tobelem G. Endothelial cell growth: biology and pharmacology in relation to angiogenesis. Blood Coagul Fibrinolysis 1990;1:703-5.
27. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizare T, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;22:1739-46.
28. Yu WD, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. (Bethesda) 1998;90:134-41.
29. Oikarinen A, Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin Exp Dermatol 1991;16:416-9.
30. Bouma-ter Steege JC, Baeten CI, Thijssen VL, Satijn SA, Verhoeven IC, Hillen HF, et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res 2004;10:7171-8.
31. Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 2000;93:634-9.
32. Nupponen I, Repo H, Kari A, Pohjavuori M, Andersson S. Early dexamethasone decreases expression of activation markers on neutrophils and monocytes in preterm infants. Acta Paediatr 2002;9:1200-7.
33. Walsh CJ, Wyffels JT, Bodine AB, Luer CA. Dexamethasone-induced apoptosis in immune cells from peripheral circulation and lymphomyeloid tissues of juvenile clearnose skates, Raja eglanteria. Dev Comp Immunol 2002;26:623-33.
34. Li H-P, He G-J, Yi X-H, Paplan AP. The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats. Respirology 2004;9:25-32.
35. Lin EY, Pollard JW. Macrophages: modulators of breast cancer progression. Novartis Found Symp 2004;256:158-68.